Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gottlieb's Tweets: Skirting The Rules Or Advancing Policy?

Executive Summary

The current FDA commissioner discussed use of the social media platform with his predecessor Robert Califf at a meeting on real-world evidence.

You may also be interested in...



COVID-19, The US FDA – And Twitter

It is far from the most important aspect of the government response to the global pandemic, but the COVID-19 outbreak includes some memorable milestones in the embrace of social media as a communication tool by the US FDA – and some individual FDAers.

US FDA To Publish Own Datasets In Latest Signal Of Enhanced Transparency

Adverse event reporting data will also be more readily available, Commissioner Scott Gottlieb says.

What Trump’s FDA Commissioner Could Teach Trump About Twitter

President Trump and his FDA Commissioner, Scott Gottlieb, are both pioneers in using social media in their government roles while also being media savvy in the old-fashioned sense. The similarities end there.

Related Content

Topics

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel